Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

PRPaweł RobakKKKihyun KımEGEsther González García

Discussion

Loading...

Member takes

Overview

Subgroup analysis shows prolonged progression-free survival in high-risk multiple myeloma patients treated with belantamab mafodotin.

Key Points

  • This research aims to evaluate the effectiveness of belantamab mafodotin in treating high-risk relapsed/refractory multiple myeloma.
  • Conducted subgroup analysis of DREAMM-7 and DREAMM-8 trials.
  • Compared belantamab mafodotin with standard treatments (bortezomib-dexamethasone and pomalidomide-dexamethasone).
  • Assessment of progression-free survival and overall survival as primary endpoints.
  • Belantamab mafodotin showed superior progression-free survival compared to standard therapies in high-risk patients.
  • Higher rates of minimal residual disease negativity were noted with belantamab mafodotin.
  • Adverse events reported included high rates in treatment arms, particularly with standard therapies.

Cite This Study

Robak et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d185https://doi.org/10.1182/blood-2025-5820
View Full Paper
Ask AI
Bookmark
Share